CardiaTec Biosciences

CardiaTec Biosciences is a Cambridge-based TechBio company using advanced computational methods to decode the complex biology underpinning cardiovascular disease — the world's leading cause of death, responsible for 17.9 million lives lost annually. Despite this enormous disease burden, cardiovascular drug discovery has been chronically underfunded and hindered by a limited understanding of the multifactorial mechanisms driving the disease. CardiaTec was founded in 2021 as a spin-out from the Han Lab at the University of Cambridge to address this gap directly, combining AI with large-scale human multi-omics data.

CardiaTec's platform integrates whole genome sequencing, transcriptomics, epigenomics, and proteomics data derived from a proprietary network of over 65 hospitals across the US and UK, where human cardiac tissues are collected on a 24/7 basis. This has enabled the company to build what it describes as the first and largest human heart tissue multi-omics dataset, which is then analysed using state-of-the-art computational modelling and machine learning to identify novel and differentiated drug targets. The company's mission is to discover first-in-class therapeutics that challenge the current standard of cardiovascular care.

Co-founded by CEO Raphael Peralta, COO Thelma Zablocki, and CTO Professor Namshik Han — all affiliated with the University of Cambridge — CardiaTec raised $6.5 million in a seed round in September 2024 led by Montage Ventures, with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures. The funding is being used to expand the company's platform and advance proprietary drug targets into wet lab validation.